Saidha S, Bell J, Harold S, Belisario JM, Hawe E, Shao Q, Wyse K, Maiese EM. Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis. Neurol Sci. 2023 May;44(5):1515-32. doi: 10.1007/s10072-022-06582-y
Skajaa N, Adelborg K, Horvath-Puho E, Rothman KJ, Henderson VW, Thygesen LC, Sorensen HT. Stroke and risk of mental disorders compared with matched general population and Myocardial infarction comparators. Stroke. 2022 Jul;53(7):2287-98. doi: 10.1161/STROKEAHA.121.037740
Jeyakumar G, Tu JV, Austin PC, Hall R, Jin A, Manuel D, Silver FL, Swartz R, Chu A, Khan AM, Kapral MK. Rural-urban differences in stroke incidence, mortality and risk factor prevalence in Ontario. Poster presented at the American Heart Association/American Stroke Association 2017 International Stroke Conference; February 21, 2017. Houston, TX. [abstract] Stroke. 2017 Feb; 48(Suppl_1):180. doi: 10.1161/str.48.suppl_1.wp180
Williams VS, Nelson LM, Fehnel SE, MacDougall J, Carson RT, Tourkodimitris S, Kurtz C, Baird MJ, Johnston JM. Psychometric validation of symptom severity measures in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2014 Aug;40(3):298-308. doi: 10.1111/apt.12830
Rubin DT, Mody R, Davis KL, Wang CC. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727
Shah S, Murthy S, Karanth S, Bershad EM, Venkatasubba Rao CP, Suarez JI. Treatment of ischemic stroke with recombinant tissue plasminogen-activator in pregnancy: a population study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1). doi: doi.org/10.1161/str.45.suppl_1.wp61Stroke. 2014;45:AWP61
Murthy S, Shah S, Karanth S, Shastri A, Bershad E, Suarez JI. Clinical outcomes following thrombolysis for acute ischemic stroke in patients with primary brain tumors: a nationwide population study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1). doi: 10.1161/str.45.suppl_1.tmp14Stroke. 2014;45:ATMP14
Murthy S, Shah S, Karanth S, Shastri A, Bershad E, Suarez JI. Clinical outcomes following thrombolysis for acute ischemic stroke in patients with systemic malignancy: a nationwide case-control study. Poster presented at the International Stroke Conference 2014; February 2014. San Diego, CA. [abstract] Stroke. 2014 Feb; 45(Suppl 1).
Murthy SB, Karanth S, Shah S, Shastri A, Rao CP, Bershad EM, Suarez JI. Thrombolysis for acute ischemic stroke in patients with cancer: a population study. Stroke. 2013 Dec;44(12):3573-6. doi: 10.1161/STROKEAHA.113.003058
Huerta C, Rivero E, Montoro MA, García-Rodriguez LA. Risk factors for intestinal ischaemia among patients registered in a UK primary care database: a nested case-control study. Aliment Pharmacol Ther. 2011 Apr;33(8):969-78. doi: 10.1111/j.1365-2036
Earnshaw SR, Klok RM, Iyer S, McDade C. Methylnaltrexone bromide for the treatment of opioid-induced constipation in patients with advanced illness--a cost-effectiveness analysis. Aliment Pharmacol Ther. 2010 Apr 1;31(8):911-21.
Earnshaw SR, Jackson D, Farkouh R, Schwamm L. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis. Stroke. 2009 May 1;40(5):1710-20.
Earnshaw SR, Jackson DL, Farkouh RA, Schwamm LH. Cost-effectiveness of MRI-based selection of patients for intravenous thrombolysis. Poster presented at the 2009 International Stroke Conference; February 2009. San Diego, CA. [abstract] Stroke. 2009 Apr; 40(4):E192-3.
Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, Mangel AW, Fehnel SE. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008 Jun 15;27(12):1224-32.
Tennis P, Andrews E, Hickman P, Miller D, Hollis KA, Cook S. The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme. Aliment Pharmacol Ther. 2007 Feb 1;25(3):317-22.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke. 2006 Nov 28;37(11):2751-8.
Earnshaw SR, Joshi AV, Wilson MR, Rosand J. Cost-effectiveness of recombinant activated factor vii in the treatment of intracerebral hemorrhage. Poster presented at the 2006 International Stroke Conference; February 17, 2006. [abstract] Stroke. 2006 Nov; 37(11):2751.
Miller DP, Bennett L, Hollis KA, Tennis P, Cook SF, Andrews E. A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. Aliment Pharmacol Ther. 2006 Sep 1;24(5):869-78.
Mangel AW, Fehnel SE. Global endpoints in functional gastrointestinal disease. Aliment Pharmacol Ther. 2005 Dec 1;22(11-12):1162-3.
Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen VZ, Hamm LR, Mangel AW, Tennis P, Cook SF. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther. 2005 Nov 10;22:935-42.
Djousse L, Rothman KJ, Cupples LA, Arnett DK, Ellison RC. Relation between serum albumin and carotid atherosclerosis the NHLBI family heart study. Stroke. 2003 Jan 1;34(1):53-7.
Clarkson TB, Anthony MS, Mikkola TS, St. Clair RW. Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke. 2002 Nov;33(11):2700-3.
Vakil N, Hahn B, McSorley DJ. Recurrent symptoms and gastro-oesophageal reflux disease in patient with duodenal ulcer treated for helicobacter pylori infection. Aliment Pharmacol Ther. 2000 Jan;14(1):45-51.
Camilleri M, Mayer EA, Drossman DA, Heath AT, Dukes GE, McSorley DJ, Kong S, Mangel AW, Northcutt AR. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther. 1999 Sep;13(9):1149-59.
Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate (tritec) plus clarithromycin is effective for healing duodenal ulcers, eradicating h.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther. 1996;10(3):251-61.